Stay updated on Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.

Latest updates to the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page now shows a revision label: v3.3.2 replacing v3.3.1 in the site footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedBranding for the Moffitt Cancer Center Clinical Trials website and a 'Helpful Links Provided by' section were added, and the revision label updated from v3.2.0 to v3.3.1.SummaryDifference0.2%

- Check28 days agoChange DetectedRemoved the site-wide government funding/operating status notice from the page.SummaryDifference0.4%

- Check43 days agoChange DetectedThe study record for NCT03514017 shows updated details such as the last update date (now 2025-09-22) and associated study dates, including enrollment and results posting timeline.SummaryDifference0.4%

- Check71 days agoChange DetectedMajor update to version (v3.2.0) and a government-operating-status notice; removal of a specific resource topic (B-cell chronic lymphocytic leukemia).SummaryDifference6%

- Check78 days agoChange DetectedUpdates modernize and expand page metadata to reflect a newer version (v3.1.0) and recent dates (September 2025), while removing older metadata (May 2025, v3.0.2).SummaryDifference1%

Stay in the know with updates to Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.